8-K: Aprea Therapeutics Gets Nasdaq Bid Price Extension

Aprea Therapeutics has received an additional 180-day period from Nasdaq to regain compliance with the minimum bid price requirement.

Summary

• Aprea Therapeutics, Inc. received a notification from Nasdaq on July 23, 2026, regarding its continued listing.
• The company has been granted an additional 180 calendar days, until January 19, 2027, to meet the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market.
• Previously, on January 23, 2026, Aprea Therapeutics received a deficiency notice for failing to meet this requirement and was initially given until July 22, 2026, to comply.
• To regain compliance, the closing bid price of the Company's common stock must be at least $1.00 per share for a minimum of 10 consecutive business days during this new period.
• Failure to demonstrate compliance by January 19, 2027, will result in written notification of delisting from Nasdaq, with an option to appeal to a hearings panel.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral development; while the extension is positive, the underlying issue of not meeting the bid price requirement persists, creating ongoing risk.

Positives

• Granted an additional 180-day period by Nasdaq to regain compliance with the minimum bid price requirement, extending the deadline to January 19, 2027.
• The company has the opportunity to regain compliance by achieving a closing bid price of at least $1.00 for 10 consecutive business days.

Negatives

• The company's common stock has not yet met the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market.
• The company previously received a deficiency notice on January 23, 2026, indicating a failure to meet the minimum bid price requirement.

Risks

• Potential delisting from The Nasdaq Capital Market if the minimum bid price requirement of $1.00 is not met by January 19, 2027.
• The company may need to consider strategic alternatives if it cannot regain compliance with Nasdaq's listing rules.

Future Outlook

The company has until January 19, 2027, to achieve a closing bid price of at least $1.00 per share for 10 consecutive business days to maintain its listing on The Nasdaq Capital Market. Failure to do so will result in delisting.

Industry Context

StockSavvy.ai notes that maintaining a minimum bid price is a common challenge for smaller biotechnology companies, often reflecting market sentiment and funding concerns. This extension provides Aprea Therapeutics with crucial time to address its stock performance.

Stakeholder Impact

• Shareholders: Continued listing on Nasdaq is crucial for liquidity and investor confidence. Delisting could negatively impact share price and trading volume.
• Creditors: Continued listing may provide more stability, while delisting could raise concerns about the company's financial health and ability to service debt.

Next Steps

• Monitor the closing bid price of the common stock to ensure it meets or exceeds $1.00 for 10 consecutive business days by January 19, 2027.
• If compliance is not achieved, Aprea Therapeutics may appeal Nasdaq's delisting determination to a hearings panel.

Key Dates

Recommendation

The company has been granted an extension to regain compliance with Nasdaq's minimum bid price rule, which avoids immediate delisting. However, the core issue of the low stock price remains unresolved, creating uncertainty. A 'hold' recommendation reflects this balance of temporary relief and ongoing risk.

Keywords

Nasdaq compliance, minimum bid price, delisting risk, stock listing, biotechnology, capital markets